Here's Why It's Unlikely That Austar Lifesciences Limited's (HKG:6118) CEO Will See A Pay Rise This Year
May 16
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Clinical Research and Equipment Industry Analysis
UpdatedJun 05, 2025
DataAggregated Company Financials
Companies9
- 7D7.8%
- 3M3.6%
- 1Y107.9%
- YTDn/a
In the last week, the Clinical Research and Equipment industry is up 3.8%, with WuXi Biologics (Cayman) leading the way, up 7.7%. This takes the industry's 12 month performance to a gain of 103%. As for the next few years, earnings are expected to grow by 32% per annum.
Industry Valuation and Performance
Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 05 Jun 2025 | HK$208.7b | HK$36.2b | HK$2.6b | 28x | 80.1x | 5.8x |
| Sat, 03 May 2025 | HK$197.0b | HK$35.4b | HK$2.5b | 27.3x | 77.6x | 5.6x |
| Mon, 31 Mar 2025 | HK$224.6b | HK$35.6b | HK$2.6b | 30.6x | 88.1x | 6.3x |
| Wed, 26 Feb 2025 | HK$199.9b | HK$35.8b | -HK$1,057,904,176.47 | 56.3x | -189x | 5.6x |
| Fri, 24 Jan 2025 | HK$153.2b | HK$35.8b | -HK$1,060,836,392.39 | 54.3x | -144.4x | 4.3x |
| Sun, 22 Dec 2024 | HK$156.5b | HK$35.7b | -HK$1,059,187,344.54 | 60.5x | -147.7x | 4.4x |
| Tue, 19 Nov 2024 | HK$135.1b | HK$36.0b | -HK$1,058,297,462.62 | 43x | -127.7x | 3.8x |
| Thu, 17 Oct 2024 | HK$148.7b | HK$35.7b | -HK$659,357,511.11 | 24.3x | -225.5x | 4.2x |
| Sat, 14 Sep 2024 | HK$147.3b | HK$35.9b | -HK$659,882,883.69 | 24.7x | -223.2x | 4.1x |
| Mon, 12 Aug 2024 | HK$100.9b | HK$35.0b | HK$2.5b | 17.5x | 40.6x | 2.9x |
| Wed, 10 Jul 2024 | HK$86.1b | HK$33.4b | HK$3.1b | 18.4x | 28x | 2.6x |
| Fri, 07 Jun 2024 | HK$89.9b | HK$33.5b | HK$3.1b | 24.7x | 29.1x | 2.7x |
| Sun, 05 May 2024 | HK$112.5b | HK$33.5b | HK$3.1b | 32.3x | 36.4x | 3.4x |
| Tue, 02 Apr 2024 | HK$116.9b | HK$33.6b | HK$3.1b | 34.4x | 37.7x | 3.5x |
| Thu, 29 Feb 2024 | HK$138.0b | HK$32.3b | HK$3.0b | 54.5x | 46.4x | 4.3x |
| Sat, 27 Jan 2024 | HK$169.8b | HK$32.5b | HK$3.0b | 69.7x | 56.4x | 5.2x |
| Mon, 25 Dec 2023 | HK$201.0b | HK$32.5b | HK$3.0b | 92.1x | 66.8x | 6.2x |
| Wed, 22 Nov 2023 | HK$295.8b | HK$32.2b | HK$3.0b | 86.8x | 99.3x | 9.2x |
| Fri, 20 Oct 2023 | HK$244.0b | HK$30.1b | HK$2.7b | 44x | 91.6x | 8.1x |
| Sun, 17 Sep 2023 | HK$235.4b | HK$30.2b | HK$2.7b | 41.8x | 87.6x | 7.8x |
| Tue, 15 Aug 2023 | HK$232.5b | HK$28.3b | HK$2.7b | 23.6x | 86.4x | 8.2x |
| Thu, 13 Jul 2023 | HK$202.6b | HK$28.5b | HK$2.7b | 22.1x | 74.2x | 7.1x |
| Sat, 10 Jun 2023 | HK$238.2b | HK$28.7b | HK$2.8b | 20.7x | 85.9x | 8.3x |
| Mon, 08 May 2023 | HK$254.2b | HK$29.5b | HK$2.9b | 22.9x | 87x | 8.6x |
| Wed, 05 Apr 2023 | HK$240.2b | HK$29.6b | HK$3.0b | 16x | 80.3x | 8.1x |
| Fri, 03 Mar 2023 | HK$301.0b | HK$26.3b | HK$2.0b | 25x | 146.9x | 11.4x |
| Sun, 29 Jan 2023 | HK$372.9b | HK$26.6b | HK$2.1b | 28.8x | 175x | 14x |
| Tue, 27 Dec 2022 | HK$284.9b | HK$26.0b | HK$2.0b | 24.9x | 142.6x | 10.9x |
| Thu, 24 Nov 2022 | HK$251.0b | HK$25.6b | HK$1.9b | 24.4x | 133.6x | 9.8x |
| Sat, 22 Oct 2022 | HK$226.6b | HK$25.5b | HK$1.8b | 20.5x | 123.1x | 8.9x |
| Mon, 19 Sep 2022 | HK$271.9b | HK$26.1b | HK$2.0b | 23.2x | 136.6x | 10.4x |
| Wed, 17 Aug 2022 | HK$368.3b | HK$22.2b | HK$2.0b | 11.7x | 181.7x | 16.6x |
| Fri, 15 Jul 2022 | HK$419.3b | HK$22.4b | HK$2.1b | 13.6x | 202.7x | 18.7x |
| Sun, 12 Jun 2022 | HK$359.7b | HK$22.4b | HK$2.1b | 14.4x | 173.3x | 16.1x |
Price to Earnings Ratio
173.3x
Current Industry PE
- Investors are optimistic on the Hong Kong Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 78.8x which is higher than its 3-year average PE of 32.8x.
- The 3-year average PS ratio of 7.5x is higher than the industry's current PS ratio of 5.7x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have grown 7.7% per year over the last three years.
- Revenues for these companies have grown 17% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Hong Kong Clinical Research and Equipment compare with similar industries?
| HK Market | 1.80% | |
| Healthcare | 9.20% | |
| Life Sciences | 7.83% | |
| Clinical Research and Equipment | 7.83% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$25.20 | 7.7% +HK$7.4b | 113.9% | PE28x | |
| 2268 WuXi XDC Cayman | HK$42.05 | 14.3% +HK$6.3b | 164.5% | PE43.3x | |
| 1548 Genscript Biotech | HK$13.08 | 3.2% +HK$870.9m | 45.7% | PS6.1x | |
| 2228 XtalPi Holdings | HK$4.63 | 4.0% +HK$723.6m | n/a | PS64x | |
| 8225 China Health Group | HK$0.17 | 0.6% +HK$995.4k | 48.2% | PS5.7x |